title: [Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
abstract: OBJECTIVE
  To explore the effects of Qinghuang Power (QHP) combined Chinese herbs for Shen reinforcing and Pi strengthening (CHSRPS) on activated T cells of myelodysplastic syndrome (MDS) patients.
  
  
  METHODS
  The percentage and the absolute value of CD3+ CD28+, CD3+ CD28+ CD4+ CD8-, CD3+ CD28+ CD8+ CD4-, CD3+ CD25+, CD3+ CD25+ CD4+ CD8-, CD3+ CD25+ CD8+ CD4-, CD3+ DR+, CD3+ DR+ CD4+ CD8-, and CD3+ DR+ CD8+ CD4- in the peripheral blood of 24 MDS patients were detected by flow cytometry before and after treatment by QHP combined CHSRPS for 9 months. The changes of the differences in the aforesaid indices were analyzed between the effective group and the in-, and CD3 + effective group.
  
  
  RESULTS
  The absolute values of CD3+ CD28+, CD3+ CD28+ CD4+ CD8-, and CD3+ CD28+ CD8+ CD4- obviously decreased in the effective group(13 cases)after treatment (P <0.05). The percentages of the three indices also obviously decreased in the ineffective group (11 cases, P <0.05). After treatment, both the percentage and the absolute value of CD3+ CD25+ and CD3+ CD25+ CD4+ CD8- obviously decreased in the effective group (P <0.05). There was no statistical difference in the two indices of the ineffective group between before and after treatment (P >0.05).
  
  
  CONCLUSIONS
  QHP combined CHSRPS could induce second signal loss by decreasing the expressions of in vitro costimulatory molecules, resulting in deactivation of T cells. It also could suppress the hyperfunction of the immune state in MDS patients, thus preventing normal hematopoietic cells from immune attack induced apoptosis.
authors.affiliation: Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. xyg312@yahoo.com.cn
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.forename: Rou
authors.initials: R
authors.lastname: Ma
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Yang
authors.forename: Yong-gang
authors.initials: YG
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D001152:Arsenicals / Q000627:therapeutic use*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D008517:Phytotherapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism*; D055815:Young Adult
chemical_list: D001152:Arsenicals; D004365:Drugs, Chinese Herbal; C570774:qinghuang